AU2011322553B2 - Liposome-based construct comprising a peptide modified through hydrophobic moieties - Google Patents

Liposome-based construct comprising a peptide modified through hydrophobic moieties Download PDF

Info

Publication number
AU2011322553B2
AU2011322553B2 AU2011322553A AU2011322553A AU2011322553B2 AU 2011322553 B2 AU2011322553 B2 AU 2011322553B2 AU 2011322553 A AU2011322553 A AU 2011322553A AU 2011322553 A AU2011322553 A AU 2011322553A AU 2011322553 B2 AU2011322553 B2 AU 2011322553B2
Authority
AU
Australia
Prior art keywords
peptide
disease
protein
liposome
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011322553A
Other languages
English (en)
Other versions
AU2011322553A1 (en
Inventor
David Hickman
Andreas Muhs
Andrea Pfeifer
Maria Pihlgren Bosch
Pedro Reis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of AU2011322553A1 publication Critical patent/AU2011322553A1/en
Application granted granted Critical
Publication of AU2011322553B2 publication Critical patent/AU2011322553B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
AU2011322553A 2010-10-26 2011-10-26 Liposome-based construct comprising a peptide modified through hydrophobic moieties Active AU2011322553B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10188832 2010-10-26
EP10188832.9 2010-10-26
PCT/EP2011/068797 WO2012055933A1 (en) 2010-10-26 2011-10-26 Liposome-based construct comprising a peptide modified through hydrophobic moieties

Publications (2)

Publication Number Publication Date
AU2011322553A1 AU2011322553A1 (en) 2013-04-18
AU2011322553B2 true AU2011322553B2 (en) 2015-07-02

Family

ID=44872345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011322553A Active AU2011322553B2 (en) 2010-10-26 2011-10-26 Liposome-based construct comprising a peptide modified through hydrophobic moieties

Country Status (10)

Country Link
US (1) US9687447B2 (https=)
EP (1) EP2632434B1 (https=)
JP (1) JP6027011B2 (https=)
KR (1) KR101854943B1 (https=)
CN (1) CN103189050B (https=)
AR (1) AR083561A1 (https=)
AU (1) AU2011322553B2 (https=)
CA (1) CA2813833C (https=)
TW (1) TW201223561A (https=)
WO (1) WO2012055933A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140314837A1 (en) * 2011-09-23 2014-10-23 Ac Immune S. A. Vaccine Therapy
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
CN103601796B (zh) * 2013-11-11 2016-09-21 杭州璞题生物科技有限公司 亨廷顿蛋白的棕榈化修饰方法
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
EP3136096B1 (en) 2014-04-23 2021-12-01 Nichirei Biosciences Inc. Combination for target marker detection
AU2015269412B2 (en) * 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
US20200297867A1 (en) * 2016-02-01 2020-09-24 Exicure, Inc. Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
JP2020526558A (ja) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
EP3735422A1 (en) 2018-01-05 2020-11-11 AC Immune SA Misfolded tdp-43 binding molecules
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
EP3773712A1 (en) * 2018-04-10 2021-02-17 AC Immune SA Anti-abeta therapeutic vaccines
WO2020023445A1 (en) * 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
KR20210154179A (ko) 2019-04-18 2021-12-20 에이씨 이뮨 에스.에이. 치료 및 진단용 신규한 분자
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
CN113853214A (zh) 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
KR20220012270A (ko) 2019-05-23 2022-02-03 에이씨 이뮨 에스.에이. 항-tdp-43 결합 분자 및 이의 용도
MX2022002873A (es) * 2019-09-10 2022-03-25 Ac Immune Sa Nuevas moleculas para diagnostico.
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CA3159964A1 (en) 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
WO2021174075A1 (en) * 2020-02-27 2021-09-02 Adeptrix Corp. Multiplexed bead-based analytical assays
US20220287970A1 (en) * 2020-06-30 2022-09-15 Eyegene Inc Composition for inhibiting saponin-induced hemolysis, containing cationic liposome
EP4196162A1 (en) 2020-08-14 2023-06-21 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
CR20240378A (es) 2022-02-16 2024-10-03 Ac Immune Sa Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas
EP4504775A1 (en) 2022-04-08 2025-02-12 AC Immune SA Anti-tdp-43 binding molecules
JP2026505011A (ja) 2023-01-26 2026-02-10 エイシー イミューン ソシエテ アノニム リポソーム構築物
JP2026503655A (ja) 2023-01-26 2026-01-29 エイシー イミューン ソシエテ アノニム 抗Ａβワクチン療法
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (en) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic T cell response protective against a virus
WO1994010198A1 (en) * 1992-11-02 1994-05-11 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
WO2005081872A2 (en) * 2004-02-20 2005-09-09 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
IT1257893B (it) 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
JP3759759B2 (ja) 1994-03-04 2006-03-29 日本油脂株式会社 リポソームおよび薬物運搬体
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
IL132236A0 (en) 1997-04-16 2001-03-19 American Home Prod Beta - amyloid peptide - binding proteins and polynucleotides encoding the same
JP4385152B2 (ja) 1997-09-17 2009-12-16 三菱化学株式会社 ２価反応性水溶性高分子誘導体及びそれを含有する複合体
KR19990029749A (ko) 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
WO1999041279A2 (en) 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6025160A (en) 1998-07-22 2000-02-15 Smithkline Beecham Corporation Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
DK1259563T4 (en) 1999-12-22 2016-11-21 Nektar Therapeutics PROCEDURE FOR PREPARING 1-BENZOTRIAZOLYL CARBONATE ESTERS OF WATER SOLUBLE POLYMERS
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
JP2002047298A (ja) 2000-07-10 2002-02-12 Academia Sinica 新規抗がん剤伝達系
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
CA2418036A1 (en) 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP5153986B2 (ja) 2000-09-06 2013-02-27 アベンティス・ファーマ・ソシエテ・アノニム アミロイドーシスと関連する疾患のための方法及び組成物
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
ATE277952T1 (de) 2001-06-12 2004-10-15 Wiltfang Jens Monoklonaler antikörper, mbab 1e8, welcher für die zwei ersten n-terminalen aminosäuren von amyloid-beta-peptiden spezifisch ist und dessen verwendung zum nachweis von amyloid-beta peptiden und/oder sappa
ES2279869T3 (es) 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2003039467A2 (en) 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
US20030229013A1 (en) 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA05008156A (es) 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
FR2857875A1 (fr) 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
ES2385226T3 (es) * 2004-02-20 2012-07-19 Ac Immune S.A. Métodos y composiciones que comprenden construcciones supramoleculares
EP1836218A2 (en) 2004-12-17 2007-09-26 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
US8394758B2 (en) 2008-10-29 2013-03-12 Academia Sinica Tumor-targeting peptides and uses thereof
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (en) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic T cell response protective against a virus
WO1994010198A1 (en) * 1992-11-02 1994-05-11 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
WO2005081872A2 (en) * 2004-02-20 2005-09-09 Ac Immune Sa Methods and compositions comprising supramolecular constructs

Also Published As

Publication number Publication date
EP2632434A1 (en) 2013-09-04
AU2011322553A1 (en) 2013-04-18
US20130224287A1 (en) 2013-08-29
JP6027011B2 (ja) 2016-11-16
CN103189050A (zh) 2013-07-03
AR083561A1 (es) 2013-03-06
KR101854943B1 (ko) 2018-05-04
TW201223561A (en) 2012-06-16
US9687447B2 (en) 2017-06-27
WO2012055933A1 (en) 2012-05-03
EP2632434B1 (en) 2025-08-20
KR20140009206A (ko) 2014-01-22
JP2014503475A (ja) 2014-02-13
CN103189050B (zh) 2017-09-29
CA2813833A1 (en) 2012-05-03
CA2813833C (en) 2020-09-22

Similar Documents

Publication Publication Date Title
AU2011322553B2 (en) Liposome-based construct comprising a peptide modified through hydrophobic moieties
US9289488B2 (en) Vaccine engineering
AU2018269742B2 (en) Nano-enabled immunotherapy in cancer
CN105524160B (zh) 药物组合物
KR102396026B1 (ko) 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
JP2014503475A5 (https=)
US8946380B2 (en) Liposome allowing liposome-entrapped substance to escape from endosome
TW201932138A (zh) Ｔａｕ胜肽之組成物及其用途
JP2025529210A (ja) アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
JP2002534481A (ja) 抗癌ワクチン接種のための抗体の使用
KR20160005380A (ko) 백신 요법
TW201804987A (zh) 以艾弗林受體Ａ２（ＥｐｈＡ２）為標靶的歐洲紫杉醇產生之奈米微脂體組成物
CA3214934A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
HK1185262A (en) Liposome-based construct comprising a peptide modified through hydrophobic moieties
HK1185262B (en) Liposome-based construct comprising a peptide modified through hydrophobic moieties
US9518114B2 (en) Treating bladder tumor cells using fibronectin attachment protein as a target
EP4228692A1 (en) Methods of treating diffuse large b-cell lymphoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)